Dexcom Inc
DXCM
View Detailed Chart
69.970USD
+0.080+0.11%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
27.29BMarket Cap
37.99P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.11%
5 Days
-4.20%
1 Month
+0.11%
6 Months
-8.42%
Year to Date
+5.42%
1 Year
-20.78%
View Detailed Chart
TradingKey Stock Score of Dexcom Inc
Currency: USD Updated: 2026-02-06Key Insights
Dexcom Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 39 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 86.02.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Dexcom Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Dexcom Inc Highlights
StrengthsRisks
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 38.60% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.03B.
Undervalued
The company’s latest PE is 37.99, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 388.08M shares, increasing 0.05% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 103.84K shares of this stock.
Analyst Rating
Based on
31
analysts
Buy
Current Rating
86.015
Target Price
+23.07%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Dexcom Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Dexcom Inc Info
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Ticker SymbolDXCM
CompanyDexcom Inc
CEOMr. Jacob Steven (Jake) Leach
Websitehttps://www.dexcom.com/
Related Instruments
+2.98%
+0.07%
+1.60%
+2.48%
+0.31%
-1.14%
-0.05%
-2.35%
-1.78%
+2.65%
+2.59%
+2.03%
+2.01%
+2.38%
+1.74%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68976.790
-993.340 (-1.42%)
282.580
+22.390 (+8.61%)
2041.390
-10.340 (-0.50%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
